Published in
American Society of Hematology, Blood, 9(130), p. 1132-1143
DOI: 10.1182/blood-2016-11-752840
Links
Tools
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis
Journal article published in 2017 by
Kellie R. Machlus 
,
Stephen K. Wu,
Prakrith Vijey,
Thomas S. Soussou,
Zhi-Jian Liu,
Eran Shacham,
T. J. Unger,
Trinayan Kashyap,
Boris Klebanov,
Martha Sola-Visner,
Marsha Crochiere,
Joseph E. Italiano,
Yosef Landesman
,
Stephen K. Wu,
Prakrith Vijey,
Thomas S. Soussou,
Zhi-Jian Liu,
Eran Shacham,
T. J. Unger,
Trinayan Kashyap,
Boris Klebanov,
Martha Sola-Visner,
Marsha Crochiere,
Joseph E. Italiano,
Yosef Landesman
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points XPO1 blockade causes thrombocytopenia by inhibiting TPO signaling and blocking the differentiation of stem cells into megakaryocytes. Selinexor-induced thrombocytopenia is reversible when TPO agonists are administered in the absence of selinexor (drug holiday).